Stock Analysis
Wave Life Sciences Ltd. (WVE) Stock Analysis
Wave Life Sciences Ltd. (WVE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Wave Life Sciences Ltd. (WVE) currently has an AIQ Score of 40/100, indicating a neutral setup. Quality is the strongest factor at 59/100. Momentum is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
WVE at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $4.59 |
| AIQ Score | 40/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $979.33M |
| P/E Ratio | -4.69 |
| Forward P/E | — |
| EPS | -$0.34 |
| Revenue TTM | $2.27M |
| Dividend Yield | 0.00% |
| Beta | -1.29 |
| Volume | 2.21M |
| 52-week range | $4.56-$21.73 |
| RSI 14 | 26.97 |
| 50-Day SMA | $5.54 |
| 200-Day SMA | $9.26 |
| Analyst Price Target | $14.33 |
| Next Earnings | Nov 9, 2026 |
Create a free account to keep researching stocks
You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.
WVE
OverviewWVE Stock Analysis Summary
Wave Life Sciences Ltd. (WVE) currently has an AIQ Score of 40/100, indicating a neutral setup. Quality is the strongest factor at 59/100. Momentum is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, WVE has AIQ Score of 40/100 with Quality base of 59/100 and fading Momentum at 25/100. Wait for component alignment before adding exposure.
Quality (59/100) leads while Momentum (25/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.71% stock move · WVE classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is WVE Bullish or Bearish Right Now?
WVE currently has a neutral overall setup. Quality is the strongest factor at 59/100, while Momentum is weakest at 25/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +212.20% upside from the latest quote.
- - Value is the current constraint at 34/100.
- - Momentum is weak at 25/100.
- - Risk Resilience is weak at 40/100.
- - Price is -50.46% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (38 vs 7).
Current Consensus
WVE's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 0 neutral, and 38 sell votes. WVE's 14-day RSI is 26.97, which places the stock in an oversold momentum range. WVE's beta is -1.29, indicating lower market sensitivity than the broad market.
What Changed in WVE?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the WVE Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
WVE Decision Framework
Public evidence layers, setup checks, and risk context for Wave Life Sciences Ltd..
Wave Life Sciences Ltd. (WVE) Stock Analysis
Wave Life Sciences Ltd. has an AIQ Score of 40/100 in a Neutral regime. Quality is strongest at 59/100. Beta is -1.29, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | WVE is in a Neutral AIQ regime with score 40/100. |
| Signal Conflict | The primary conflict is that quality leads at 59/100 while momentum lags at 25/100. |
| Factor Evidence | Momentum 25/100 · Value 34/100 · Quality 59/100 · Risk 40/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 59/100.
Momentum is 25/100 and RSI (14) is 27.0.
WVE is in a Neutral regime at 40/100.
Risk factor is 40/100 with beta -1.29 and annual volatility 168.13%.
Current conflict: quality leads at 59/100 while momentum lags at 25/100.
WVE Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
WVE Fundamentals
WVE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
WVE Technical Analysis
WVE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
WVE Stock Catalysts
Track WVE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
WVE Dividend Analysis
WVE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
WVE Financial Data
WVE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
WVE Risk Analysis
WVE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
WVE Stock News
WVE stock news, market tone, recent headlines, and catalyst context.
WVE vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: WVE · XNCR · ACAD · ALNY · ARWR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| WVE Current stock | 40/100 | 34/100 | 25/100 | 40/100 | 0.26 | 168.13% | Current |
| XNCR Xencor | 45/100 | 34/100 | 47/100 | 55/100 | 1.88 | 67.18% | WVE vs XNCR |
| ACAD Acadia Pharmaceuticals | 67/100 | 57/100 | 47/100 | 71/100 | 0.5 | 37.75% | WVE vs ACAD |
| ALNY Alnylam Pharmaceuticals | 54/100 | 26/100 | 57/100 | 42/100 | -1.19 | 46.84% | WVE vs ALNY |
| ARWR Arrowhead Pharmaceuticals | 37/100 | 34/100 | 36/100 | 57/100 | 1.97 | 60.92% | WVE vs ARWR |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 11, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching WVE
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for WVE
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
WVE Stock FAQ
What is WVE stock price today?
Wave Life Sciences Ltd.'s current stock price is $4.59. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is WVE bullish or bearish right now?
WVE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is WVE's market cap?
WVE's market cap is $979.33M based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is WVE's current P/E ratio?
WVE's current P/E ratio is -4.69 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is WVE's RSI?
WVE's 14-day RSI is 26.97 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is WVE above its 50-day and 200-day moving averages?
WVE is -17.20% from its 50-day SMA and -50.46% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is WVE's next earnings date?
WVE's next earnings date is currently listed as Nov 9, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does WVE pay a dividend?
WVE's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.